Premium
GENETIC SUBTYPE GUIDED RITUXIMAB‐BASED IMMUNOCHEMOTHERAPY IMPROVES OUTCOME IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA: FIRST REPORT OF A RANDOMIZED PHASE 2 STUDY
Author(s) -
Zhang M,
Xu P,
Wang L,
Cheng S,
Zhao W
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.26_2879
Subject(s) - medicine , diffuse large b cell lymphoma , chop , oncology , rituximab , clinical endpoint , lenalidomide , lymphoma , phases of clinical research , vincristine , gastroenterology , clinical trial , multiple myeloma , cyclophosphamide , chemotherapy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom